Cancer Cell Therapy

T-Cell Lymphoma

>18 yrs; Relapsed or refractory disease second/third line

CCT5041
Phase I
Anti-CD70
CRISPR-Cas9-Engineered TCells(CTX130) in Relapsed/Refractory T/B Cell Malignancies
PI: Weng
Sponsor: Pending

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Immunotherapy
- Trial Posting
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu